Wegovy Wins English Funding For Weight Loss As Novo Deals With Supply Issues
Executive Summary
Unprecedented demand for Wegovy in the US, together with issues experienced at the contract manufacturing site that resulted in supply shortages, led to Novo Nordisk having to wait some time for NICE to publish its final recommendation for the drug’s use on the National Health Service in England.
You may also be interested in...
UK ABPI Suspends Novo Nordisk Over Code Breach
Novo Nordisk has been given a two-year suspension from membership of the Association of the British Pharmaceutical Industry for breaching the association’s code of practice.
Two Firsts For Keytruda As NICE Says Yes To English Funding For Advanced Cervical Cancer
Keytruda is the first new cervical cancer treatment to be appraised by the health technology assessment institute, NICE, in nearly 15 years, says MSD.
EU Crunch Time For Mirikizumab, New Covid-19 Vaccine & Other Drugs
The European Medicines Agency’s human medicines committee, the CHMP, is this week deciding whether to back marketing approval for eight new drugs and a coronavirus vaccine.